New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
08:06 EDTSTEMStemCells CEO says difficult to understand stock performance last year
StemCells posted a letter to shareholders from its President and CEO Martin McGlynn, stating in part: "As CEO, one of my easiest and most gratifying jobs is to report our persistent progress to you real evidence that StemCells, Inc. continues to be a clear frontrunner. What is more difficult is trying to understand our Company's stock performance for the year just ended. We have reached out to usually well-informed third parties in the analyst and investor communities to help us understand this dynamic, but have been unable to identify anything unusual or particularly enlightening...StemCells, Inc. is in the unique position of concurrently developing novel product candidates for major medical conditions that have thus far defied traditional treatments, in all three components of the CNS: the spinal cord...the eye...and the brain...If we succeed in bringing our HuCNS-SC cells to market for even one of these indications, we believe it will be very meaningful to patients, shareholders and society at large...In 2013, we closed on approximately $54.6M in fresh capital, $29.3M of which is debt, including the committed forgivable loan from the CIRM of up to $19.3M. We start 2014 with a little over $30M in the bank, and we expect to receive the second tranche of non-dilutive funding from the CIRM, again $3.8M, later this month."
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
07:17 EDTSTEMStemCells coverage assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Yi Chen assume coverage on StemCells with a Buy rating and $2.10 price target.
November 19, 2015
09:16 EDTSTEMOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Keurig Green Mountain (GMCR), up 19%... (CTRP), up 11.8%... (CRM), up 5.4%... Perry Ellis (PERY), up 4%. ALSO HIGHER: Celladon (CLDN), up 55.9% after signing a merger agreement with Eiger BioPharmaceuticals... StemCells (STEM), up 45.7% after Phase II Pathway Study data shows motor improvement in SCI patients... UniPixel (UNXL), up 36.1% after receiving an initial mass production order from a Japanese PC manufacturer... Anavex Life Sciences (AVXL), up 16% after announcing preparation of regulatory filings based on guidance from FDA... Plug Power (PLUG), up 3.7% after securing Colruyt Group as its next GenDrive fuel cell customer in Europe. DOWN AFTER EARNINGS: Stage Stores (SSI), down 14.7%... JinkoSolar (JKS), down 7.5%... Best Buy (BBY), down 5.2%... Semtech (SMTC), down 7.5%. ALSO LOWER: AMAG Pharmaceuticals (AMAG), down 8.4% after receiving a complete response letter from the FDA its application seeking approval for a single-dose vial of Makena... Titan International (TWI), down 8.3% after being downgraded to Sell from Neutral at Goldman... Sunedison (SUNE), down 5.5% after Reuters reported that Blackstone (BX) is not interested in SunEdison investment.
November 18, 2015
16:09 EDTSTEMStemCells Phase II Pathway Study data shows motor improvement in SCI patients
StemCells announced that the six-month interim results for the first cohort in its ongoing Phase II Pathway Study in cervical spinal cord injury, or SCI, showed motor improvements in both strength and function. The assessment of motor function involved using tests of dexterity. Patients eligible for the study have complete loss of motor control below the level of injury, the most severe degree of SCI as defined by the American Spinal Injury Association Impairment Scale, or AIS. Clinicians used both ISNCSCI, or International Standards for Neurological Classification of Spinal Cord Injury, and GRASSP, or Graded Assessment of Strength Sensibility and Prehension, measures to establish a pre-transplant baseline for each patient and to assess post-transplant progress. This first cohort of the Pathway Study was designed to assess the safety, and preliminary signs of efficacy, of cell administration into the cervical cord and select the dose level for the 40-patient second cohort, a randomized, controlled and single-blinded arm of the trial, which is already underway. Based on six-month follow-up, for the first cohort, an overall pattern of motor improvement was detected in four of the six patients as measured by gains in both strength and function on the collective ISNCSCI and GRASSP outcomes.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use